Abstract
Mycophenolate mofetil (MMF) is a relatively new immunomodulatory agent. The experience of MMF in inflammatory eye diseases is limited to a few case series. We report our experience of MMF in eight patients with uveitis. Control of inflammation was achieved in all patients. No patient had adverse side effects. Our study indicates that MMF is a safe and effective immunomodulatory agent.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nussenblatt RB (1990) The natural history of uveitis. Int Ophthalmol 14:303–308
Vadot E, Barth E, Billet P (1984) Epidemiology of uveitis—preliminary results of a prospective study in Savoy. In: Saari KM (ed) Uveitis update. Elsevier, Amsterdam, pp 13–16
Rothova A, Suttorp-van Schulten MS, Treffers WF et al (1996) Causes and frequency of blindness in patients with intraocular inflammatory eye disease. Br J Ophthalmol 80:332–336
Jabs DA, Rosenbaum JT, Foster CS et al (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130:492–513
Lipsky JJ (1996) Mycophenolate mofetil. Lancet 348:1357–1359
Epinette WW, Parker CM, Jones EL et al (1987) Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 17:962–971
Ahsan N, Johnson C, Gonwa T et al (2001) Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation 72:245–250
European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 345:1321–1325
Kirklin JK, Bourge RC, Naftel DC et al (1994) Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transpl 13:444–450
Adu D, Cross J, Jayne DR (2001) Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 10:203–208
Schwarz A (2001) New aspects of the treatment of nephritic syndrome. J Am Soc Nephrol 12(Suppl 17):S44–S47
Goldblum R (1998) Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 11(Suppl 8):S117–S119
Chanaud III NP, Vistica BP, Eugui E et al (1995) Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. Exp Eye Res 61:429–434
Kilmartin DJ, Fletcher ZJ, Almeida JA et al (2001) CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis. Invest Ophthalmol Vis Sci 42:1285–1292
Kilmartin DJ, Forrester JV, Dick AD (1998) Rescue therapy with mycophenolate mofetil in refractory uveitis [letter]. Lancet 352:35–36
Larkin G, Lightman S (1999) Mycophenolate mofetil: a useful immunosuppressive in inflammatory eye disease. Ophthalmology 106:370–374
Baltatzis S, Tufail F, Yu EN et al (2003) Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 110:1061–1065
Sen HN, Suhler EB, Al-Khatib SQ et al (2003) Mycophenolate mofetil for the treatment of scleritis. Ophthalmology 110:1750–1755
Greiner K, Varikkara M, Santiago C et al (2002) Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis. Ophthalmologe 99:691–694
Zierhut M, Stubiger N, Aboalchamat W et al (2001) Immunosuppressive therapy with mycophenolate mofetil (CellCept) in treatment of uveitis [German]. Ophthalmologe 98:647–651
Lau CH, Comer M, Lightman S (2003) Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Exp Ophthalmol 31:487–491
Thorne JE, Jabs DA, Qazi FA et al (2005) Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 112:1472–1477
Michel SS, Ekong A, Baltatazis S et al (2002) Multifocal choroiditis and panuveitis: immunomodulatory therapy. Ophthalmology 109:378–383
Howe LJ, Stanford MR, Edelsten C et al (1994) The efficacy of systemic corticosteroids in sight-threatening retinal vasculitis. Eye 8:443–448
Joseph A, Raj D, Dua HS et al (2003) Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 110:1449–1453
Baughman RP, Lower EE, Bradley DA et al (2005) Etanercept for refractory ocular sarcoidosis: results of a double-blind, randomized trial. Chest 128(2):1062–1047
Papliodis GN, Chu D, Foster CS (2003) Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 110:786–789
Dick AD, Azim M, Forrester JV (1997) Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporine A. Br J Ophthalmol 81:1107–1112
Rigotti P, Cadrobbi R, Baldan N et al (2000) Mycophenolate mofetil (MMF) versus azathioprine (AZA) in pancreas transplantation: a single-center experience. Clin Nephrol 53:52–54
Miserocchi E, Balatzis S, Ekong A et al (2002) Efficacy and safety of chlorambucil in intractable noninfectious uveitis. Ophthalmology 109:137–142
Sampson CM, Waheed N, Balatatzis S et al (2001) Methotrexate therapy for chronic noninfectious uveitis. Ophthalmology 108:1134–1139
Acknowledgement
This work was financially supported by Vision Research Foundation, Chennai, India.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rathore, V.M., Agrawal, R., Chaudhary, S.P. et al. Mycophenolate mofetil therapy in uveitis: analysis of eight cases in a tertiary ophthalmic care centre in India. Int Ophthalmol 29, 117–122 (2009). https://doi.org/10.1007/s10792-007-9179-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-007-9179-x